ArticleWorld journal of gastroenterology2025
Repeat ablation and single-session ablation in patients with multiple colorectal cancer liver metastases after chemotherapy failure.
Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe feasibility and safety of radiofrequency ablation (RFA) for oligometastatic colorectal liver metastases (CRLM) have been well established. However, the role of RFA in multiple metastases after first-line chemotherapy failure remains underexplored.
aimTo assess long-term survival and factors affecting outcomes of RFA in patients with multiple refractory CRLM.
methodsA retrospective study was conducted on patients who underwent ablation of CRLM at our institution between January 2015 and June 2024. A total of 80 patients were included, with 42 individuals receiving single-session ablation and 38 underwent repeat ablation. Enhanced computed tomography imaging was utilized to evaluate procedural efficacy 24 hours post-RFA, followed by follow-up scans every 3-4 months. Progression-free survival (PFS) and overall survival (OS) rates were compared at endpoint using Kaplan-Meier curves. Cox regression was used to identify the factors associated with OS and PFS.
resultsThe technical success rate was recorded at 98.7%. At endpoint, 42 (52.5%) patients achieved tumor-free survival, while 28 (35%) remained alive with residual tumors present. No significant OS/PFS differences existed between single-session (median follow-up 29.5 months, median PFS 24.5 months) and repeat ablation (30 months, 14 months) cohorts (
conclusionFor patients with multiple refractory CRLM, both single-session ablation and repeat ablation can increase the proportion of patients achieving tumor-free status. However, careful consideration is necessary for ablation of metastases larger than 2.7 cm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.